BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38644978)

  • 1. Estradiol induces bone osteolysis in triple-negative breast cancer via its membrane-associated receptor ERα36.
    Cohen DJ; Dennis CD; Deng J; Boyan BD; Schwartz Z
    JBMR Plus; 2024 May; 8(5):ziae041. PubMed ID: 38644978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 17β-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model.
    Cohen DJ; Patel V; Verma A; Boyan BD; Schwartz Z
    Steroids; 2019 Feb; 142():28-33. PubMed ID: 29133279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estradiol enhances osteolytic lesions in mice inoculated with human estrogen receptor-negative MDA-231 breast cancer cells in vivo.
    Winding B; Misander H; Høegh-Andersen P; Brünner N; Foged NT
    Breast Cancer Res Treat; 2003 Mar; 78(2):205-16. PubMed ID: 12725420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumol inhibits breast cancer growth
    Wei ZL; Juan W; Tong D; Juan LX; Sa LY; Jie HFM; Xiao G; Xiang LG; Jie HM; Xu C
    Food Funct; 2023 Jan; 14(2):874-885. PubMed ID: 36537297
    [No Abstract]   [Full Text] [Related]  

  • 5. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
    Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
    Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
    [No Abstract]   [Full Text] [Related]  

  • 6. Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer.
    Maczis MA; Maceyka M; Waters MR; Newton J; Singh M; Rigsby MF; Turner TH; Alzubi MA; Harrell JC; Milstien S; Spiegel S
    J Lipid Res; 2018 Dec; 59(12):2297-2307. PubMed ID: 30315000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteolytic effects of tumoral estrogen signaling in an estrogen receptor-positive breast cancer bone metastasis model.
    Cheng JN; Frye JB; Whitman SA; Kunihiro AG; Brickey JA; Funk JL
    J Cancer Metastasis Treat; 2021; 7():. PubMed ID: 34790880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17Beta-estradiol promotes aggressive laryngeal cancer through membrane-associated estrogen receptor-alpha 36.
    Schwartz N; Chaudhri RA; Hadadi A; Schwartz Z; Boyan BD
    Horm Cancer; 2014 Feb; 5(1):22-32. PubMed ID: 24081562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.
    Clohisy DR; Palkert D; Ramnaraine ML; Pekurovsky I; Oursler MJ
    J Orthop Res; 1996 May; 14(3):396-402. PubMed ID: 8676252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
    Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
    J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor-alpha 36 mediates the anti-apoptotic effect of estradiol in triple negative breast cancer cells via a membrane-associated mechanism.
    Chaudhri RA; Hadadi A; Lobachev KS; Schwartz Z; Boyan BD
    Biochim Biophys Acta; 2014 Nov; 1843(11):2796-806. PubMed ID: 25108195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
    Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
    J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERα36 as a Potential Therapeutic Target for Tamoxifen-Resistant Breast Cancer Cell Line Through EGFR/ERK Signaling Pathway.
    Li G; Zhang J; Xu Z; Li Z
    Cancer Manag Res; 2020; 12():265-275. PubMed ID: 32021441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitin Mediated Degradation of EGFR by 17 β-estradiol in Triple Negative MDA-MB-231 (TNBC) Breast Cancer Cells Line.
    Khode V; Patil S; Kaveeshwar V; Ruikar K; Bargale A; E S; Patil S
    Curr Mol Med; 2022; 22(5):449-457. PubMed ID: 34376133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
    Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
    Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.